Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
generic viagra online
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets For The Treatment Of Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.
News of the day
Earliest Possible Causes Of Autism Studied By NIH Autism Center Of Excellence Network
A network of leading autism researchers from three regions across the country has launched one of the largest research studies of its kind to investigate early risk factors for Autism Spectrum Disorders (ASD). The network, called the Early Autism Risk Longitudinal Investigation (EARLI), will follow a cohort of up to 1,200 pregnant women who already have a child with autism. The study is considered one of the best-equipped to discover biological markers and environmental risk factors for autism due to its elevated autism risk pregnancy cohort, wide ranging data collection with extensive bio-sampling, length of time it follows pregnant women and their babies, and multi-disciplinary team of expert investigators.
Health Insurance

A Combination Of Micronutrients Is Beneficial In Reducing The Incidence Of Prostate Cancer And Increasing Survival In The Lady Transgenic Model

UroToday.com - Dietary micronutrients are a common component of people"s diet as they seek to prevent cancer and other diseases. Micronutrients protect against cellular oxidative damage by neutralizing oxygen free radicals. In the May 2009 issue of Cancer Prevention Research, Dr. VasundaraVenkateswaran and associates tested the effects and timing of the micronutrients vitamin E (E), selenium (S), and lycopene (L) on the development of prostate cancer (CaP) in the Lady transgenic model. Transgenic male mice were randomized to the following groups; control diet, or control diet supplemented with a combination of E+S+L started at either 4, 8, 20, or 36 weeks of age. This experiment sought to investigate if the preventive effect of micronutrients was mediated by inhibiting cancer initiation or progression. Another experimental objective was to examine the micronutrients that were essentially contributing to this reduced incidence. To do this, transgenic male mice were randomized at 4 weeks of age to one of the following diets; control diet, control diet with a combination of E+S, and control diet supplemented with a combination of E+S+L. Mice were sacrificed and tissue and blood examined at 58 weeks of age. Weight gain was similar among groups. At 58 weeks of age there was a significant increase in the survival proportion of the animals in all of the intervention groups compared with the controls. Either E+S or E+S+L or diet supplemented with E+S+L initiated at 8, 20, and 36 weeks of age showed a significant increase in median survival compared with controls. Control mice would not be continued on the diet beyond 48 weeks of age due to tumor burden. Among control mice, 75% developed CaP and 16.7% high grade PIN. Only 10% of mice supplemented at 4 weeks of age with E+S+L developed tumors. Use of E+S+L when commenced by 8 weeks of age resulted in a highly significant reduction in CaP incidence. When micronutrients were commenced at 20 and 36 weeks of age, none of the mice had normal prostates. In control mice, liver metastasis were present in 75%, but in only 10% and 15.4% when micronutrients were started at 4 and 8 weeks, respectively. Early administration of micronutrients resulted in reduced the expression of proliferative marker PCNA and increased the extent of apoptosis. It also altered cell cycle regulation with up-regulation of the prognostic tissue marker p27kip1. Among all histologic, survival and molecular parameters assessed, it was apparent that lycopene was essential to the beneficial outcome. Despite the negative outcome of the SELECT trial, these data suggest that the early administration of micronutrients is important in experimental models. Venkateswaran V, Klotz LH, Ramani M, Sugar LM, Jacob LE, Nam RK, Fleshner NE Cancer Prev Res (Phila Pa). 2009 May;2(5):473-83 10.1158/1940-6207.CAPR-08-0124 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009